by • March 9, 2016 • No Comments
3D printing is big, but bioprinting has rapidly turn it intod into a thing substantially extra
; in fact, it’s become an huge–and fascinating–realm of its own, which should donate us all cause for excitement and optimism. And leading the way is Organovo, with a team which can be proud to understand they are well on their way to effecting huge alter in medical research.
Based in San Diego, the 3D biology company is rapidly being best known as one of the top innovators in the scientific and health fields, as they turn it into functional human tissue with their new innovation. Whilst breakthroughs lately in bioprinted kidney tissue have had them in the news (this exVive3D product is scheduled for release in the third quarter), earning astounding acclaim and attention, their firstly product, exVive 3D Human Liver Tissue, is the subject of five presentations at the Society of Toxicology’s (SOT) 55th Annual Meeting and ToxExpo, of March 13–17 in New Orleans.
The detailed presentations can every work to educate and explain how the exVive 3D Human Liver Models allow for ‘broad applicability’ in enabling scientists and medical professionals to assess drug safety , as well as being able-bodied to detect a range of liver injuries, to include steatosis, or ‘fatty liver’ and fibrosis, which is the first states of liver scarring which can lead to cirrhosis.
“Organovo’s exVive3D Human Liver Model provides an accurate, predictive and reproducible version of human liver biology for preclinical toxicity testing,” said Paul Gallant, general manager, Organovo. “At the SOT Annual Meeting, we and our pharmaceutical customers can be highlighting new results which show our 3D bioprinted human liver tissue effectively versions in vivo tissue composition and physiology.”
One leading theme running through their presentations in addition is which with these new versions, the require for testing on animals may be nearer to elimination—and especially as the results are inferior to what Organovo’s versions can contribute, ultimately.
“Drug-induced liver injury remains a leading cause of late-stage clinical failures and market withdrawal, frequently due to poor translation of preclinical animal studies to clinical outcomes,” said Dr. Sharon Presnell, chief innovation officer and executive vice president of research & createment, Organovo.
“Organovo’s exVive3D human liver version replicates hard cell-cell interactions and key elements of native tissue architecture to enable-bodied the detection of multiple clinically-relevant modes of tissue injury, which include necrosis, immune-mediated tissue injure, steatosis, and fibrosis. When a preclinical or clinical-stage asset presents a challenging safety or efficacy signal, exVive3D provides the one-of-a-kind resolving power of a regulated human tissue microenvironment to investigate mechanism and create solutions.”
Investigating in vitro mechanisms of drug-induced liver injury with biochemical and histologic endpointsEvaluating liver toxicity caused by long term compound treatment, as well as liver recovery after drug removalCapturing the spectrum of drug-induced alters at the tissue level, which include reduced liver function and vascular reversioningDemonstrating drug, chemical, and TGF-β1 induced liver fibrosis at the cellular, molecular, and histologic levelInterrogating and identifying over time the key cellular and molecular events underlying fibrogenesisCharacterizing the short and long-term impacts of acetaminophenExamining immune-mediated, drug-induced liver injury
Organovo can contribute an exhibitor-hosted session on March 15, at 9:00 a.m. Central Time (CT), in Room 212 to include oral presentations on new makes it to via bioprinted 3D human liver tissues to assess drug-induced liver toxicity. It can be presented by Sharon Collins Presnell, Ph.D., of Organovo, and Umesh M. Hanumegowda, MVSc Ph.D. DABT, of Bristol-Myers Squibb.
Following which is the lineup of presentations for the day, to include:
Poster Presentations: March 15, 9:30 a.m. – 12:45 p.m. CT, at CC Exhibit Hall
Title:Functional Evaluation of Bioprinted Human Liver Organoid as a Liver Injury Model
Presenter: Kazuhiro Tetsuka, Ph.D., Astellas Pharma Inc.
Poster: 2001: Poster Board – P405
Title:Modeling Drug Induced Hepatic Fibrosis In Vitro Working with Three-Dimensional Liver Tissue Constructs
Poster: 1996: Poster Board – P348
Title:Utilization of exVive3D Human Liver Tissues for the Evaluation of Valproic Acid Induced Liver Injury
Presenter: Candace Grundy, Organovo
Poster: 2003: Poster Board – P407
Title:Inflammatory Response of Kupffer Cells in 3D Bioprinted Human Liver Tissues
Presenter: Rhiannon N. Hardwick, Ph.D., Organovo
Poster: 1959: Poster Board – P311
Late-breaking Poster Presentation: March 17, 9:30 a.m. – 12:45 p.m. CT, Great Hall A
Title: Monocrotaline Toxicity in 3D Bioprinted Human Liver Tissue
Presenter: Umesh M. Hanumegowda, MVSc Ph.D. DABT, Bristol-Myers Squibb
Poster: 3562: Poster Board – P254
The Organovo Exhibit Booth can in addition be visited of March 14-16, of 9:15 a.m. – 4:30 p.m. CT, in Booth 1701, at CC Exhibit Hall.
We can be releasing extra
information regarding the content of the presentations future week, so remain tuned to find out extra
of what the Organovo team and their group of presenters had to say. Their latest createments are indeed significant for everyone to learn of as with their innovations they can be able-bodied to accelerate drug discovery processes, allow for faster and extra
low-priced-bodied treatment, as well as improving toxicology procedures and preclinical drug testing. They in addition have extra
products in createment.
You can find out extra
of this company and their use of 3D human tissue in research and therapeutic applications here. Discuss in the exVive3D Human Liver Model Presentations at SOT forum over in 3DPB.com.
by admin • March 5, 2017
by admin • November 28, 2016
by admin • November 28, 2016